Alternative production of Bcl-2 and Bax by tumor cells determines the rates of in vivo tumor progression: Suggested mechanisms

Journal of Cellular Biochemistry

Volumn 101, Issue 5, 2007, Pages 1148-1164

  Deichman, Galina I ^a   Dyakova, Natalya A ^a   Matveeva, Valentina A ^a   Kashkina, Lydia M ^a  

^a N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

Author keywords

Acceleration and delay; Bax; Bcl 2; HP phenotype; HSP90 HSP70; Ras; Tumor progression

Indexed keywords

HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; PROTEIN BAX; PROTEIN BCL 2; RAS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL TRANSFORMATION; CONTROLLED STUDY; EMBRYO; MALIGNANT TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN SYNTHESIS; SYRIAN HAMSTER; TUMOR CELL; TUMOR GROWTH;

ANIMALS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; CRICETINAE; DISEASE PROGRESSION; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MESOCRICETUS; MODELS, BIOLOGICAL; NEOPLASMS; PHENOTYPE; RAS PROTEINS; SELECTION (GENETICS);

CRICETINAE;

EID: 34547882728     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21242     Document Type: Article

References (59)

1. Adams JM, Cory S. 1998. The Bcl-2 protein family: Arbiters of cell survival. Science 281(5381):1322-1326.
2. Bauer G. 1996. Elimination of transformed cells by normal cells: A novel concept for the control of carcinogenesis. Histol Histopathol 11:237-255.
3. de La Coste A, Mignon A, Fabre M, Gilbert E, Porteu A, Van Dyke T, Kahn A, Perret C. 1999. Paradoxical inhibition of c-myc-induced carcinogenesis by Bcl-2 in transgenic mice. Cancer Res 59(19):5017-5022.
4. Deichman GI. 1988. Natural host resistance and in vivo selection of malignant tumor cells. Cancer Surveys 7(4): 675-690.
5. Deichman GI. 2000. Natural selection and early changes of phenotype of tumor cells in vivo: acquisition of new defense mechanisms. Biochemistry (Mosc). 65(1): 78-94.
6. Deichman GI. 2002. Early phenotypic changes of in vitro transformed cells during in vivo progression: Possible role of the host innate immunity. In Sem Cancer Biol 12(4):317-326.
7. Deichman GI, Vendrov EL. 1986. Characteristics of in vitro transformed cells essential for their in vivo survival, selection and metastasizing activity. Int J Cancer 37: 401-409.
8. Deichman GI, Kluchareva TE, Matveeva VA, Kushlinsky NE, Bassalyk LS, Vendrov EL. 1989. Clustering of discrete cell properties essential for tumorigenicity and metastasis. I. Studies of Syrian hamster embryo fibroblasts spontaneously transformed in vitro. Int J Cancer 44:904-907.
9. Deichman GI, Gurova KV, Dyakova NA. 1994 . Accumulation in the "normal" Lungs of live tumorigenic cells during subcutaneous growth of weakly and highly metastasizing tumors and their susceptibility to growth regulation by normal fibroblasts. Int J Cancer 59:530-537.
10. ras. Int J Cancer 66:747-752.
11. Deichman GI, Matveeva VA, Kashkina LM, Dyakova NA, Uvarova EN, Nikiforov MA, Gudkov AV. 1998. Cell transforming genes and tumor progression: In vivo unified phenotypic secondary cell changes. Int J Cancer 75(2):277-283.
12. Dotto GP, Weinberg RA, Ariza A. 1988. Malignant transformation of mouse primary keratinocytes by Harvey sarcoma virus and its modulation by surrounding normal cells. PNAS 85:6389-6393.
13. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. 2002. Cancer immunoediting: From immuno-surveillance to tumor escape. Nature immunology 3:991-998.
14. S) phenotype in conditions of subcutaneous growth and dissemination. Dokl Biol Sci 378:283-286.
15. 125I-5-Iodo-2′-deoxyuridine. J Natl Cancer Inst 45:733-782.
16. Fidler IJ. 2003. The pathogenesis of cancer metastasis: The 'seed and soil' hypothesis revisited. Nat Rev Cancer 3:453-458.
17. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ. 1996. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379:88-91.
18. Gurova KV, Gudkov AV. 2003. Paradoxical role of apoptosis in tumor progression. J Cell Biochem 88(1):128-137.
19. Gurova KV, Kwek SS, Koman IE, Komarov AP, Kandel E, Nikiforov MA, Gudkov AV. 2002 . Apoptosis inhibitor as a suppressor of tumor progression: Expression of Bcl-2 eliminates selective advantages for p53-deficient cells in the tumor. Cancer Biol Ther 1:39-44.
20. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. 1994. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 54(8):2095-2097.
21. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100:57-70.
22. Hanusch J, Schwieger A, Sers C, Schafer R, Bauer G. 2000. Oncogenic transformation increases the sensitivity for apoptosis induction by inhibitors of macromolecular synthesis. Int J Oncol 17:89-95.
23. Heigold S, Sers C, Bechtel W, Ivanovas B, Schafer R, Bauer G. 2002. Nitric oxide mediates apoptosis induction selectively in transformed fibroblasts compared to non-transformed fibroblasts. Carcinogenesis 23(6):929-941.
24. 2-terminal BH4 domain of Bcl-2 is functional for heterodimerization with Bax and inhibition of apoptosis. J Biol Chem 274(29):20415-20420.
25. Howard JC, Li Q, Chu W, Zochodne B, Kapoor M, Ung Y, Rosen K, Ben-David Y. 2001. Bcl-2 expression in F-MuLV-induced erythroleukemias: A role for the antiapoptotic action of Bcl-2 during tumor progression. Oncogene 20(18):2291-2300.
26. Hsu YT, Youle RJ. 1997. Nonionic detergents induce dimerization among members of the Bcl-2 family. JBC 272:13829-13834.
27. Ionov Y, Yamamoto H, Krajewski S, Reed JC, Perucho M. 2000. Mutational inactivation of the proapoptotic gene Bax confers selective advantage during tumor clonal evolution. PNAS 97(20):10872-10877.
28. Jolly C, Morimoto RI. 2000. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst 92(19):1564-1572.
29. Kashkina LM, Matveeva VA, Dyakova NA, Uvarova EN, Deichman GI. 2004. Acquisition of HP phenotype and alterations in the activity of catalase of in vitro transformed cells of different origin in the dynamics of in vivo tumor progression. Dokl Biol Sci 394:94-97.
30. Klein G. 2002. Introduction: Genetic and epigenetic contribution to tumor evolution. Sem Cancer Biol 12:327-330.
31. Klein G. 2004. Cancer, apoptosis, and nonimmune surveillance. Cell Death Different 11:13-17.
32. Klein G, Klein E. 2005. Surveillance against tumors - Is it mainly immunological? Immunol Lett 100(1):29-33.
33. Kluchareva TE, Matveeva VA, Kushlinsky NE. 1992. In vitro bioassay for type E prostaglandins based on their NK immunodepressing activity. Imm Lett 33(3):239-246.
34. Knudson CM, Korsmeyer SJ. 1997. Bcl-2 and Bax function independently to regulate cell death. Nat Genet 16(4): 358-363.
35. Knudson CM, Johnson GM, Lin Y, Korsmeyer SJ. 2001. Bax accelerates tumorigenesis in p53-deficient mice. Cancer Res 61(2):659-665.
36. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
37. Luke JJ, van der Wetering CJ, Knudson CM. 2003. Lymphoma development in Bax transgenic mice is inhibited by Bcl-2 and associated with chromosomal instability. Cell Death Different 6:540-548.
38. Magistrelli P, Coppola R, Tonini G, Vincenzi B, Santini D, Borzomati D, Vecchio F, Valeri S, Castri F, Antinori A, Nuzzo G, Caraglia M, Picciocchi A. 2006. Apoptotic index or a combination of Bax/Bcl-2 expression correlate with survival after resection of pancreatic adenocarcinoma. J Cell Biochem 97(1):98-108.
39. Miyashita T, Reed JC. 1995. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80(2):293-299.
40. Nowell PS. 1986. The clonal evolution of tumor cell subpopulations. Science 194:23-28.
41. Nylandsted J, Rohde M, Brand K, Bastholm L, Elling F, Jaattela M. 2000. Selective depletion of heat shock protein 70 Hsp70 activates a tumor-specific death program that is independent of caspases and bypasses Bcl-2. PNAS 97(14):7871-7876.
42. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH. 2005. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677-681.
43. Oltvai ZN, Milliman CL, Korsmeyer SJ. 1993. Bcl-2 heterodimerizes in vivo with a conserved homolog Bax, that accelerates programmed cell death. Cell 74(4):609-619.
44. Otter I, Conus S, Ravn U, Rager M, Olivier R, Monney L, Fabbro D, Borner C. 1998. The binding properties and biological activities of Bcl-2 and Bax in cells exposed to apoptotic stimuli. J Biol Chem 273(11):6110-6120.
45. Poste G, Fidler IJ. 1980. The pathogenesis of cancer metastasis. Nature 283:139-146.
46. Price JE, Carr D, Tarin D. 1984. Spontaneous and induced metastases of naturally occurring tumors in mice: Analysis of cell shedding into the blood. J Natl Cancer Inst 73:1319-1326.
47. Price JE, Aukerman SL, Fidler IJ. 1986. Evidence that the process of murine melanoma metastasis is sequential and selective and contains stochastic elements. Cancer Res 46:5172-5178.
48. Roskelley CD, Bissell M. 2002. The dominance of microenvironment in breast and ovarian cancer. Sem Cancer Biol 12:97-104.
49. Sierra A, Castellsague X, Escobedo A, Lloveras B, Garcia-Ramirez M, Moreno A, Fabra A. 2000. Bcl-2 with loss of apoptosis allows accumulation of genetic alterations: A pathway to metastatic progression in human breast cancer. Int J Cancer 89(2):142-147.
50. Vail ME, Pierce RH, Fausto N. 2001. Bcl-2 delays and alters hepatic carcinogenesis induced by transforming growth factor alpha. Cancer Res 61(2):594-601.
51. Valdes J, Garcia E, Llorente M, Mendes E. 2003. Innovative approach to low-level gluten determination in foods using a novel sandwich enzyme-liked immunosorbent assay protocol. Eur J Gastroenterol Hepatol 15(5):465-474.
52. van Delft MF, Huang DC. 2006. How the Bcl-2 family of proteins interact to regulate apoptosis. Cell Res 16(2): 2003-2013.
53. van Slooten HJ, van de Vijver MJ, van de Velde CJ, van Dierendonck JH. 1998. Loss of Bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activity. Br J Cancer 77(5): 789-796.
54. Weinberg R. 1989. Oncogenes, anti-oncogenes and the molecular bases of multistep carcinogenesis. Cancer Res 49:3713-3721.
55. Witz IP, Sagi-Assif O, Ran M. 1996. The shaping of the malignant phenotype - An interplay between cellular characteristics and microenvironmental factors. In: Yefenof E, Scheuermann RH, editors. Premalignancy and Tumor Dormancy. Heidelberg: RG Landes Company, Springer-Verlag.
56. Yin XM. 2006. Bid, a BH3-only multifunctional molecule, is at the cross road of life and death. Gene 369:7-19.
57. Yin XM, Oltvai ZN, Korsmeyer SL. 1994. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 369(6478): 321-323.
58. Young MR, Knies S. 1984. Prostaglandin E production by Lewis lung carcinoma: Mechanism for tumor establishment in vivo. J Natl Cancer Inst 72:919-922.
59. Zornig M, Hueber A, Baum W, Evan G. 2001. Apoptosis regulators and their role in tumorigenesis. Biochim Biophys Acta 1551(2):F1-F37.